Skip to main content

Critical Care Reviews Newsletter

Newsletter 479  |  February 17th 2021

IL-6 Receptor Antagonist Domain Results Presentation is Imminent

Welcome to the 479th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature for the past seven days.

The highlights of this week's edition are the release of the preprint of the RECOVERY Collaborative Group's tocilizumab trial and an RCT investigating the effect of a restrictive vs liberal blood transfusion strategy  in patients with acute myocardial infarction and anemia; a systematic review and meta analysis on the comparative effectiveness  of  protective  ventilation  strategies  for  moderate  and  severe  ARDS; and an observational study comparing  high-flow nasal oxygen therapy and non-invasive ventilation in ICU patients with acute respiratory failure and a do-not-intubate order. There is also a Chinese consensus statement on neuro-protection after cardiac arrest; narrative reviews on endovascular resuscitation & oxygen administration for patients with ARDS; an editorial on fever management in COVID-19 patients; & a commentary on optimizing secondary outcomes in randomized controlled trials.

The first of our Spring Series of major trial results is almost here, with the imminent relase of the REMAP-CAP IL-6 receptor antagonist domain results. Hopefully, we'll have this for you very shortly. The pre-print has already been published, but the full results are now almost ready for presentation.



Randomised Controlled Trials

Systematic Reviews & Meta Analyses

Observational Studies





General Interest


I hope you find this newsletter useful.

Until next week




Supported by the Health Research Board